On December 18, 2025, President Trump signed an executive order rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA).
White House officials emphasized that this decision intends to make cannabis research less restrictive, allowing for more formal study and evaluation, particularly by the Food and Drug Administration for medical purposes.
What this decision does not do is just as important as what it does. Rescheduling cannabis does not make cannabis federally legal. It does not eliminate state-level regulations, nor does it open the floodgates for unrestricted advertising, sales, or claims.
Rescheduling is not reform, and it is definitely not legalization.
So what does this actually mean for cannabis brands, operators, and marketers trying to plan for the future? Here’s cannabis rescheduling explained: what’s changing, what’s staying the same, and what businesses need to understand before making their next move.
Why Cannabis Rescheduling Changes the Marketing Conversation
Cannabis rescheduling represents one of the most significant federal shifts the industry has seen in decades. At a high level, it opens up the doors for expanded research and medical evaluation under federal oversight.
For operators and brands, there are additional questions to consider: Can we advertise now? Can we scale faster? What’s actually legal?
The short answer is that rescheduling cannabis does not automatically lift advertising restrictions or grant broad access to mainstream ad platforms. It will, however, soften perceptions and open the door to future policy updates. In other words, there’s hope.
For now, cannabis marketing remains heavily restricted by platform rules, federal agencies, and state regulations, requiring brands to proceed with caution rather than assume new freedoms.
The real marketing impact of rescheduling marijuana that’s got the industry buzzing is the relief from IRS Section 280E, a federal tax provision that prohibits businesses involved in Schedule I or II controlled substances from deducting ordinary business expenses, such as, say, marketing services.
With cannabis enroute to being rescheduled, brands will likely be able to write off professional services like marketing, branding, SEO, and advertising, freeing up capital, which will dramatically change how aggressively and strategically brands invest in marketing.
What Does Cannabis Rescheduling Actually Mean?
The Controlled Substances Act (CSA) determines how substances are regulated based on medical use, abuse potential, and safety.
As a Schedule I drug, cannabis has so far been defined as having “no accepted medical use” and a high potential for abuse. Schedule III, however, is recognized as having accepted medical uses and a lower risk of abuse.
Schedule III currently includes drugs such as ketamine, anabolic steroids, and certain codeine-containing medications, including prescription forms of Tylenol, all of which are legal under strict federal regulation.
Here’s what’s important to know: rescheduling does not override state cannabis programs. States with established medical or adult-use markets will maintain their existing frameworks, though federal oversight may become more defined over time.
As far as marketing, labeling, and claims go, these will remain tightly regulated. However, it is still unclear how federal standards may intersect with state rules and how the government will choose to update existing restrictions accordingly.
Beyond regulation, rescheduling will likely reduce risk for ancillary services. Banks, insurers, and professional service providers may view cannabis as a safer industry to support, improving access to financial and operational resources without altering federal legality.
Schedule I vs Schedule III: Key Differences
| Category | Schedule I | Schedule III |
| Medical Recognition | No accepted medical use under federal law | Accepted medical use is recognized federally |
| Research Access | Highly restricted; limited approvals and sources | Expanded access for federally approved research |
| Regulatory Oversight | DEA oversight with severe restrictions | DEA oversight with increased FDA involvement |
| Tax Treatment (280E) | 280E applies; no deductions for ordinary business expenses | 280E may no longer apply, allowing deductions |
| Legal Status | Federally illegal | Still federally regulated, not legalized |
| Marketing & Advertising | Highly restricted | Still restricted; no automatic ad access |
| State Programs | Governed by state law | State programs remain in place |
| Examples of Substances | Heroin, LSD, MDMA | Ketamine, anabolic steroids, and codeine combinations |
Long story short: Rescheduling cannabis does not make it federally legal, erase state-level regulations, or automatically allow unrestricted advertising or sales. Compliance with federal, state, and platform rules remains essential.
What Rescheduling Does Not Change for Cannabis Marketing
This all sounds like great news, but it’s important to note that rescheduling cannabis does not open the floodgates to unrestricted marketing. The FDA still regulates health claims and medical messaging, while the Federal Trade Commission (FTC) continues to enforce advertising standards.
State-by-state regulations also remain fully in effect, meaning brands must still navigate local licensing, advertising rules, and compliance requirements. In short, rescheduling shifts classification, but does not remove the regulatory framework marketers must follow.
Advertising Platforms Do Not Automatically Open
Rescheduling cannabis does not guarantee access to major advertising platforms. Companies like Google, Meta, and TikTok continue to enforce their own policies, which currently prohibit cannabis-related ads regardless of federal classification.
Health Claims Are Still Highly Restricted
Even under Schedule III, making medical or disease-related claims remains prohibited. The FDA continues to regulate all health messaging, and the FTC enforces truth-in-advertising standards, meaning any overstated benefits can trigger penalties. As cannabis becomes more federally recognized, enforcement risk may increase, making careful, compliant communication critical for brands.
What Cannabis Rescheduling Does Change for Marketing
Increased Brand Legitimacy
With cannabis in the same category as heroin, LSD, and MDMA (ecstasy), it’s understandable that many have been skeptical of its benefits. Rescheduling cannabis to Schedule III changes the game, introducing more legitimacy. Consumers will likely start to see products as safer or more trustworthy, investors may be more willing to fund growth, retail partners could expand shelf space, and media outlets may provide more coverage. This shift positions brands to operate with greater credibility than under Schedule I restrictions.
More Sophisticated Marketing Expectations
We’ve already seen stoner-centric messaging become less effective in today’s market. As brands face pressure to present themselves as mature, credible businesses, the competition is fierce, and branding makes a difference.
With rescheduling, cannabis is going to start gaining federal recognition, and the market will naturally demand more professional and polished brand presentation. This raises the bar for messaging, user experience, and storytelling, making strategic branding a competitive necessity.
Increased Competition for Attention
As more eyes turn to the industry, we’re likely to see new entrants, increased capital and funding, and heightened competition for consumer loyalty. Marketing channels may become more crowded, and customer acquisition costs could rise as brands vie for visibility. This makes strategic, compliant, and differentiated marketing more important than ever.
Cannabis Advertising After Rescheduling: What Brands Need to Know
Can Cannabis Brands Advertise After Rescheduling?
The short answer is: it depends. While rescheduling may reduce certain federal restrictions, paid search, paid social, display, and influencer marketing channels still operate under platform-specific rules that often prohibit cannabis ads. Brands must carefully evaluate each channel’s policies before assuming advertising opportunities have expanded.
Platform-by-Platform Reality Check Reminder
Even after rescheduling cannabis, advertising policies often lag behind regulatory changes. Enforcement can be inconsistent, and each platform exercises its own risk tolerance, meaning what works for one brand may result in account suspension for another.
Why Advertising Still Isn’t the Smart First Move
Jumping into paid campaigns too quickly can be costly and risky at this stage. Brands still face the risk of account shutdown, wasted spend, and compliance exposure, making advertising a potentially dangerous first step. We anticipate this will open up as formalities are ironed out, so it’s worth setting aside some 2026 marketing budget, but focus on owned channels, SEO, and compliant content for safer, longer-term growth opportunities.
The Safest Growth Channels for Cannabis Marketing
Owned, Compliant, Scalable
Owned, compliant, and scalable channels like CRM (email and SMS) give cannabis brands direct access to customers who have already opted in, eliminating platform risk and approval barriers. These channels allow brands to deliver deals, product highlights, and personalized messaging while borrowing proven strategies from retail giants in the non-cannabis space, such as segmentation, lifecycle campaigns, and average order value (AOV) focused offers, to build stronger relationships through human-centered, conversion-driven, and data-backed content that consistently drives results.
How Rescheduling Impacts Cannabis Search Behavior
With rescheduling, cannabis-related searches are expected to surge, particularly around educational topics, brand comparisons, and legal questions. This creates a prime opportunity for brands to establish authority early, positioning themselves as trusted sources before the market becomes more competitive.
Content That Wins in a Post-Rescheduling Market
Brands that succeed will prioritize educational content, buyer’s guides, and compliance-aware storytelling. Local SEO remains critical for dispensaries, helping them attract nearby customers while staying within regulatory boundaries. Thoughtful, strategic content on other channels, such as social media, email marketing, and more, ensures visibility and credibility in a market that’s increasingly sophisticated and scrutinized.
What Cannabis Brands Should Do Right Now
With rescheduling creating both opportunity and uncertainty, cannabis brands need clear, strategic actions to stay ahead. Immediate priorities include auditing current marketing for new compliance standards and ensuring all messaging, claims, and labeling align with changing federal and state regulations.
Brands should invest in SEO and educational content, creating long-term assets that build authority and attract customers without relying on restricted ad platforms. Investing more in brand messaging to emphasize professionalism, trust, and consumer education is also critical.
At the same time, brands should continue to avoid aggressive paid media, national ad campaigns, or any marketing that makes health or medical claims. By focusing on compliant, owned channels and strengthening brand authority, companies can position themselves for growth while minimizing risk in a post-rescheduling landscape.
Your Cannabis Marketing Strategy After Rescheduling
In this new landscape, marketing prowess becomes a competitive advantage, and the winners will be those who lean into sophisticated marketing tactics, building trust with consumers, investors, and partners alike.
If you’re unsure how rescheduling impacts your marketing, we can help. Our team can review your cannabis marketing strategy and provide a clear path forward to position your business for growth in a Schedule III market.
Book a free consultation today, and we’ll audit your marketing plan for a post-rescheduling cannabis industry.